EQT Life Sciences — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
EvommuneNYSE: EVMNOct 2024SEC filingmedium confidence
Palo Alto, US
Janice Drew(Executive Officer)David Cohen(Director)Robert Hopfner(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Board seatFelice Verduyn - Van Weegen· per SEC Form D · $115.5M raise · filed Jan 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.